736 , Shakti Khund III , New Delhi

Press Release

The global immunotherapy drugs market valued USD 146.1 billon in year 2019. The immunotherapy drugs market is estimated to foresee growth at a CAGR of 9.1% during the period of 2020-2026.

COVID-19 has impacted all the businesses across the globe. World Health Organization has declared Corona virus as a global pandemic. The COVID19 has disrupted the Immunotherapy market. People across the world are afraid entering the hospitals due to corona virus. Hence due to COVID-19 the immunotherapy market is estimated to foresee decline in its initials phase of forecast period but it can witness growth in latter phase of forecast period.

For more details, visit: Global Immunotherapy Drugs Market By Type(Monoclonal Antibodies, Checkpoint Inhibitor, others), By Therapeutic Area (Cancer, Infectious Disease, Others), By End User (Hospitals, Clinics, Others), By Region–Forecast & Opportunities to 2026

The rising prevalence of chronic diseases and increasing demand for biosimilars and monoclonal antibodies are the factors driving immunotherapy market towards growth. The adoption of immunotherapy drugs largely over conventional treatments nowadays is another driving factor for immunotherapy drugs market.

On the basis of type the immunotherapy drug market is segmented into monoclonal antibodies, interferon & interleukins and checkpoint inhibitors. The monoclonal segment accounted for maximum market share in year 2019. The major driving factors are fewer side effects and specificity. Focus on personalized medicines is increasing and rise in cases of chronic diseases are driving the market.

On the basis of therapeutic area the immunotherapy drug market is segmented into cancer, Infectious diseases, auto immune & inflammatory disease and others. Cancer segment had registered maximum market share in 2019.

On the basis of end-user the immunotherapy drug market is segmented into hospitals, clinics and treatments. Hospitals accounted for maximum market share in 2019. Hospitals are spending at a large scale in immunotherapy.

Based on regions, North America was accounted for maximum market share in year 2019. It is expected to maintain its dominance during the forecast period and projected to register growth at highest CAGR during the forecast period. There are many favorable government initiatives support this market segment. The private organizations are investing more in R&D department to provide technologically advanced products. The number chronic disease cases are more in this area. In 2016, 1.75 million new cancer cases were likely to be detected in U.S.

The key market players in immunotherapy drugs market are Pfizer Inc., Novartis AG, F. HoffmannLa Roche Ltd., Johnson & Johnson, Sanofi, Glaxo Smith Kline Plc, Amgen Inc., Merk& Co., Abb Vie Inc., AstraZeneca, Immatics, Boehringer Ingelheim, Biotechnologies, BioNTech SE, Gnmab,, NBE Therapeutics, Teva Phamaceuticals, Bayer, Gilead Sciences and Bristol-Myers Squibb.


  • What are the expected industry trends over the next three to five years?
  • Which of the immunotherapy drugs type is likely to lead by 2025?
  • Which of the end-user segments is expected to have the maximum potential to during the forecast period?
  • Which region is going to have the highest smart meters market share by 2025?
  • What are different organic and inorganic strategies implemented by companies to gain increased market share?

Leave a Reply

Your email address will not be published.